Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Moonshot

- PMLiVE

Servier to acquire Agios’ oncology business in $1.8bn deal

French pharma will also gain Agios' oncology-associated employees

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

- PMLiVE

Boehringer spends €1.18bn to acquire NBE-Therapeutics

Company specialises in antibody-drug conjugate development

- PMLiVE

Moderna posts encouraging early data for personalised cancer vaccine

Vaccine tested alongside Merck's Keytruda

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

Ongoing Virtual Communication between MSLs and Physicians: a Customer Story

Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians.

Impetus Digital

- PMLiVE

Merck signs separate agreements with Seattle Genetics for two cancer drugs

Merck makes a $1bn equity investment in the biotech company

In the precision medicine era, the line between products and services is blurred

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

Blue Latitude Health

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

- PMLiVE

GlaxoSmithKline reportedly looking to sell select antibiotic brands

Sale would fund R&D efforts in other key focus areas such as oncology

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links